ArticleMedicine2025
Study on the clinical efficacy and TCM syndrome element changes of modified Longgu Muli Decoction in the treatment of chronic atrophic gastritis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Formononetin Alleviates MNNG-Triggered Chronic Atrophic Gastritis: Its Potential Mechanisms.Combinatorial chemistry & high throughput screening · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study, designed as a retrospective study, aims to investigate the clinical efficacy of Longgu Muli Decoction plus additions in treating chronic atrophic gastritis (CAG) and the changes in traditional Chinese medicine (TCM) syndromes. Sixty patients with CAG were enrolled and divided into the observation group and control group according to different treatment methods, with 30 patients in each group. The observation group received Longgu Muli Decoction plus additions, while the control group received conventional treatment. The treatment duration was 4 weeks. Clinical efficacy, TCM syndrome scores, gastrointestinal hormone levels, serum inflammatory factor levels, and sleep quality of the 2 groups were evaluated before and after treatment. Data were analyzed using SPSS 22.0 statistical software. The total effective rate in the observation group was 96.67%, significantly higher than 86.67% in the control group (P < .05). After treatment, the TCM syndrome scores, gastrointestinal hormone levels (endothelin [ET], calcitonin gene-related peptide [CGRP], epidermal growth factor [EGF]), and serum inflammatory factor levels (tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], C-reactive protein [CRP]) in the observation group were significantly better than those in the control group (P < .05). Moreover, the Pittsburgh Sleep Quality Index (PSQI) total score and various subscale scores in the observation group were significantly lower than those in the control group (P < .05). Longgu Muli Decoction plus additions has significant clinical efficacy in treating CAG. It can effectively improve gastrointestinal function, reduce inflammatory reactions, and enhance sleep quality, thus demonstrating high clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.